# Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Source: https://onco.cc/trials/nct03934372/  
OnCo record `nct03934372` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ponatinib in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Incyte Biosciences International Sàrl, now recruiting.

## Summary

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors is a phase 1/2 interventional study registered as NCT03934372 by Incyte Biosciences International Sàrl, with 70 participants planned, started 2020-01-29 and due to reach its primary completion in 2028-02-01. Interventions recorded: Ponatinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03934372
- Phase: 1/2
- Setting: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
- Sponsor: Incyte Biosciences International Sàrl
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT03934372: https://clinicaltrials.gov/study/NCT03934372

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Ponatinib](https://onco.cc/drugs/ponatinib/)

---
JSON: https://onco.cc/api/v1/entities/nct03934372.json